Clinical Trial Update: Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept study assessing a single intraarticular dose of GZ389988 versus placebo for knee osteoarthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• GZ389988 (GZ389988)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Osteoarthritis | Phase 2 | Status: COMPLETED